

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8065786

<b>SUBMISSION TYPE:</b>	CORRECTIVE ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Corrective Assignment to correct the FILING DATES LISTED ON "EXHIBIT A" OF ASSIGNMENT previously recorded on Reel 057707 Frame 0883. Assignor(s) hereby confirms the ASSIGNMENT.
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ROY LEVITT DR.	12/30/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ONSPIRA THERAPEUTICS, INC.
<b>Street Address:</b>	640 LEE ROAD
<b>Internal Address:</b>	SUITE 110
<b>City:</b>	WAYNE
<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	19087
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17366835
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(212)230-8888
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2122956498
<b>Email:</b>	alice.castro@wilmerhale.com
<b>Correspondent Name:</b>	WILMERHALE
<b>Address Line 1:</b>	7 WORLD TRADE CENTER
<b>Address Line 2:</b>	250 GREENWICH STREET
<b>Address Line 4:</b>	NEW YORK, NEW YORK 10007
<b>ATTORNEY DOCKET NUMBER:</b>	2216897.123 US7
<b>NAME OF SUBMITTER:</b>	ALICE CASTRO
<b>SIGNATURE:</b>	/Alice Castro/
<b>DATE SIGNED:</b>	07/19/2023
<b>Total Attachments: 5</b>	
source=2216897.123_US7_Levitt_to_Onspira_Corrected_Assignment#page1.tif	
source=2216897.123_US7_Levitt_to_Onspira_Corrected_Assignment#page2.tif	

source=2216897.123\_US7\_Levitt\_to\_Onspira\_Corrected\_Assignment#page3.tif

source=2216897.123\_US7\_Levitt\_to\_Onspira\_Corrected\_Assignment#page4.tif

source=2216897.123\_US7\_Levitt\_to\_Onspira\_Corrected\_Assignment#page5.tif

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6953910

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
DR. ROY LEVITT	12/30/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ONSPIRA THERAPEUTICS, INC.
<b>Street Address:</b>	640 LEE ROAD
<b>Internal Address:</b>	SUITE 110
<b>City:</b>	WAYNE
<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	19087
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17366835
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)526-5000
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	617-526-6000
<b>Email:</b>	lori.roman@wilmerhale.com
<b>Correspondent Name:</b>	WILMER CUTLER PICKERING HALE AND DORR LLP
<b>Address Line 1:</b>	60 STATE STREET
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02109
<b>ATTORNEY DOCKET NUMBER:</b>	2216897.00123US7
<b>NAME OF SUBMITTER:</b>	LORI ROMAN
<b>SIGNATURE:</b>	/Lori Roman/
<b>DATE SIGNED:</b>	10/05/2021
<b>Total Attachments: 4</b>	
source=Assignment-Levitt_to_Onspira_Executed#page1.tif	
source=Assignment-Levitt_to_Onspira_Executed#page2.tif	
source=Assignment-Levitt_to_Onspira_Executed#page3.tif	
source=Assignment-Levitt_to_Onspira_Executed#page4.tif	

## PATENT ASSIGNMENT

December 30, 2019

WHEREAS, the undersigned, Dr. Roy Levitt and Marcia Levitt, each a citizen of the United States, residing at 33 North Shore Drive, Miami Beach, FL 33141 (together, the "Assignors"), are the owners of certain intellectual property relating to the treatment of lung diseases through the use of inhaled Anakinra, including but not limited to Bronchiolitis Obliterans Syndrome and Cystic Fibrosis, among others, for which the Assignors filed certain patent applications, as further described in Exhibit A (the "Levitt IP");

WHEREAS, Onspira Therapeutics, Inc., a Delaware corporation, having a mailing address of 640 Lee Road, Suite 110, Wayne, PA 19087 (the "Assignee"), and the Assignors entered into that certain Exclusive Option Agreement, dated as of April 11, 2017, as amended pursuant to Amendment No. 1 to Exclusive Option Agreement dated as of December 18, 2017, Amendment No. 2 to Exclusive Option Agreement dated as of June 20, 2018, Amendment No. 3 to Exclusive Option Agreement dated as of September 20, 2018, Amendment No. 4 to Exclusive Option Agreement dated May 28, 2019, Amendment No. 5 to Exclusive Option Agreement dated September 20, 2019 and Amendment No. 6 to Exclusive Option Agreement dated December 9, 2019 (collectively, the "Option Agreement"), pursuant to which Assignors granted to Assignee the Option (as defined in the Option Agreement) relating to the purchase of the Levitt IP;

WHEREAS, Assignee desires to acquire the entire right, title and interest in and to the Levitt IP, including the applications for patent and the patents which were or may be granted on or as a result thereof in the United States or in any other country;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby freely acknowledged, and intending to be legally bound, the Assignors have sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over, to Assignee, and Assignee accepts, the entire right, title and interest in and to the Levitt IP, and in and to such applications for patent and any and all continuations, divisions, and renewals of and substitutes for such applications, and in, to and under any and all patents that were or may be granted on or as a result thereof in the United States and in all other countries, and any reissue or reissues or extension or extensions of such patents, the same to be held and enjoyed by Assignee, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which such patents respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by Assignors had this assignment, sale and transfer not been made;

Assignors hereby warrant and covenant that they have full right to convey the entire interest herein assigned, and that they have not executed and will not execute any agreement in conflict herewith, and further covenant and agree that they will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to the Levitt IP, such applications and such patents in Assignee, its successors, assigns, nominees, or legal representatives, and agree to communicate to Assignee or to its nominee all known facts respecting the Levitt IP, such applications and such patents, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional,

continuing, and reissue applications, to make all rightful oaths, and generally to do everything possible to aid Assignee, its successors, assigns, nominees and legal representatives to obtain and enforce for its own benefit proper patent protection for the Levitt IP in the United States and in all other countries; and


Assignors hereby authorize and request the proper governmental authority in the respective country to issue to Assignee the entire right, title and interest, in and to any and all patents for the Levitt IP as set forth on Exhibit A and any and all patents which may be issued and granted on or as a result of the applications as set forth on Exhibit A, in each case, in accordance with the terms of this Patent Assignment.

[Signature Page Follows]


IN WITNESS WHEREOF, the parties hereto have executed this Patent Assignment as of the day and year first above written.


ASSIGNEE:

ONSPIRA THERAPEUTICS, INC.

By:   
Name: Brad Loric  
Title: Chief Executive Officer

ASSIGNORS:

  
Dr. Roy Levitt

  
Marcia Levitt

[Signature Page to Patent Assignment]

Exhibit A

Title	Patent No.	Country	Sub. C. Sub.	Type	Status	Application No.	File Date	Publ. No.	Issue Date	Expire Date	Record Owner	Legal/Beneficial Owner
LOCALIZED THERAPY OF LOWER AIRWAYS INFLAMMATORY DISORDERS WITH PRO-INFLAMMATORY CYTOKINE INHIBITORS	067389-5001	Australia	01	DIV	Pending	201203630	10-Aug-07				Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		Australia	01	DIV	Granted	201203647	10-Aug-07	201203647			Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		Australia	02	DIV	Granted	201200228	10-Aug-07	201200228	10-Jun-19	10-Aug-27	Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		Australia		PCT	Abandoned	200728496	10-Aug-07				Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		Canada		PCT	Pending	2568510	10-Aug-07				Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		European Patent Convention	01	DIV	Pending	10204910	10-Aug-07				Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		European Patent Convention		PCT	Allowed	078307073	10-Aug-07	2006889	23-Oct-19	10-Aug-27	Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		Japan		PCT	Abandoned	2009-123863	10-Aug-07				Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		Patent Cooperation Treaty		OPF	Closed	PCT/US07/17808	10-Aug-07				Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		United States of America		PCT	Granted	12/371,627	10-Aug-07	2,940,683	27-Jan-15	22-Mar-30	Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		United States of America	01	CON	Allowed	14/602,545	26-Jan-15				Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		United States of America	02	CON	Pending	16/734,948	16-Dec-2019				Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		United States of America	P1	PRO	Closed	60/876,385	4-Jan-07			4-Jan-08	Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		United States of America	P2	PRO	Closed	60/901,028	16-Mar-07			16-Mar-08	Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
	United States of America	PR	PRO	Closed	60/836,760	10-Aug-06			10-Aug-07	Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt	
RHINOSINUSITIS PREVENTION AND THERAPY WITH PRO-INFLAMMATORY CYTOKINE INHIBITORS	067389-5002	Australia		PCT	Issued	2007276978	11-Jul-07	2007276978	28-Dec-12	11-Jul-17	Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		Canada		PCT	Abandoned	2657581	11-Jul-07				Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		European Patent Convention		PCT	Abandoned	078101258	11-Jul-07				Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		European Patent Convention	01	DIV	Abandoned	141903494	11-Jul-07				Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		Patent Cooperation Treaty		OPF	Closed	PCT/US07/10784	11-Jul-07				Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		United States of America		PCT	Granted	12/372,448	11-Jul-07	2,637,468	28-Jan-14	16-Jun-20	Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		United States of America	01	DIV	Abandoned	14/163,720	24-Jan-14				Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		United States of America	P1	PRO	Closed	60/876,397	4-Jan-07			4-Jan-08	Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		United States of America	P2	PRO	Closed	60/901,027	16-Mar-07			16-Mar-08	Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
		United States of America	PR	PRO	Closed	60/815,793	11-Jul-06			11-Jul-07	Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt
RHINOSINUSITIS THERAPY	067389-5003	United States of America	PR	PRO	Closed	60/812,674	12-Jun-06			12-Jun-07	Dr. Roy Lewitt	Dr. Roy & Marcia Lewitt

DMU6097433.10

PATENT

RECORDED: 07/19/2023

REEL: 064339 FRAME: 0843